This section lists details of new information added to the MHRA website.
Companies have amended their advertising following MHRA action on complaints to ensure that prescription only medicines are not promoted to the public.
20 Oct 2014 | Upostelle 1500 microgram tablet (levonorgestrel), healthcare professional advertisement, September 2014
A pharmacist complained to the MHRA about an advertisement for Upostelle aimed at pharmacists and produced by Gedeon Richter Plc/Consilient Health Ltd which appeared in the Chemist and Druggist of 20 September 2014.
20 Oct 2014 | Helicobacter Test INFAI (13C-urea), healthcare professional advertisement, August 2014
A healthcare professional complained to the MHRA about the advertising of Helicobacter Test INFAI.
17 Oct 2014 | Press release: Regulator warns dentists about the dangers of buying and using counterfeit and unapproved dental equipment
The Medicines and Healthcare products Regulatory Agency (MHRA) is warning dentists about the potential danger of buying and using counterfeit and unapproved dental equipment. This follows the seizure of over 12,000 different pieces of poor quality dental equipment imported into the UK from China and Pakistan and sold on auction websites such as eBay, Amazon and Alibaba in the past 6 months.
17 Oct 2014 | MHRA statement on misuse of laxatives
MHRA has issued a statement following the BBC Watchdog investigation into the availability of stimulant laxatives in the UK, first broadcast on Thursday 16 October.
16 Oct 2014 | EMA public consultation on functional specification for portal and database that will underpin the EU Clinical Trials Regulation (deadline 31 October 2014)
EMA have launched a public consultation on the functional specification for a portal and database that will underpin the EU Clinical Trials Regulation. Stakeholders are invited to review the document and provide comments to the EMA by 31 October 2014.
15 Oct 2014 | Class 4 Drug Alert (Caution in Use): Amoxil Vials for Injection 500mg and 1g, Augmentin Intravenous 600mg and 1.2g manufactured by Beecham Group PLC and Beecham Group Ltd trading as GlaxoSmithKline UK (EL (14)A/15)
GlaxoSmithKline has informed us of a very low incidence of cracks being found in vials used for packaging of these products.
13 Oct 2014 | Press release: ‘One stop shop’ for advice on regenerative medicine opening for business
A new ‘one stop shop’ that will provide regulatory advice for those working in the life sciences industry on exciting regenerative medicines has been launched today.
10 Oct 2014 | Information sent to healthcare professionals in September about the safety of medicines
Copies of letters sent to healthcare professionals in September 2014, to inform of new safety information and advice.
10 Oct 2014 | Press release: MHRA responds to European Medicines Agency recommendations on the use of valproate medicines
The Pharmacovigilance Risk Assessment Committee (PRAC) of the European Medicines Agency (EMA) has recommended strengthening the restrictions on the use of valproate medicines due to an increased risk of birth defects and developmental problems in children exposed to valproate in the womb.